{"id":"novohelisen-depot","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL1200775","moleculeType":"Protein","molecularWeight":"1269.47"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by mimicking the action of the natural hormone GLP-1, which helps to lower blood glucose levels by enhancing glucose-dependent insulin secretion, suppressing inappropriately elevated glucagon secretion, and slowing gastric emptying.","oneSentence":"NovoHelisen Depot is a long-acting formulation of a glucagon-like peptide-1 (GLP-1) receptor agonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:57:46.435Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT06778213","phase":"PHASE4","title":"Evaluation of the Efficacy of Allergen-specific Immunotherapy Using Assessment in an Allergen Exposure chamber-a Randomized Placebo-controlled Double-blind Study","status":"RECRUITING","sponsor":"Wroclaw Medical University","startDate":"2024-11-02","conditions":"Allergic Rhinoconjunctivitis","enrollment":67}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"NovoHelisen Depot","genericName":"NovoHelisen Depot","companyName":"Wroclaw Medical University","companyId":"wroclaw-medical-university","modality":"Biologic","firstApprovalDate":"","aiSummary":"NovoHelisen Depot is a long-acting formulation of a glucagon-like peptide-1 (GLP-1) receptor agonist. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}